Product Name: BCKDK (122-136)
Product Number: PE-01AZU90
| Size: | 200 µg | Price: | 38.00 | |
| 1 mg | $US | 77.00 | ||
| 5 mg | 166.00 |
Peptide Name: BCKDK (122-136)
Product Use: Services as a blocking peptide for use with the BCKD-2 rabbit polyclonal antibody (Cat. No.: AB-NK257-2) that is also available from Kinexus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CILHVHELYIRAFQKL
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1982.4 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Product Use: Services as a blocking peptide for use with the BCKD-2 rabbit polyclonal antibody (Cat. No.: AB-NK257-2) that is also available from Kinexus.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CILHVHELYIRAFQKL
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1982.4 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: BCKDK pan-specific antibody (Cat. No.: AB-NK257-2)
Storage Conditions: -20°C
Related Product 1: BCKDK pan-specific antibody (Cat. No.: AB-NK257-2)
Scientific Background: BCKD is a protein-serine/threonine kinase of the Atypical group and PDHK family. Its is associated with the mitochondrial matrix and features a HATPase_c domain. BCKD dimerizes through direct interaction of two opposing nucleotide-binding domains. It phosphorylates and inactivates the E1-alpha subunit of the branched-chain ketoacid dehydrogenase (BCKDK), which is involved in the catabolism of valine, leucine and isoleucine. Inactivating mutations in BCKD have been discovered in families with autism, epilepsy, and intellectual disability, a syndrome that may respond to dietary supplementation.
© Kinexus Bioinformatics Corporation 2017